Renal and metabolic effects of semaglutide plus canagliflozin <i>vs</i> canagliflozin alone in type 2 diabetic nephropathy

CSCT provided significant improvements in multiple metabolic and renal parameters without increasing adverse events, thus highlighting its potential benefits for patients with DN.

Authors

Institutions

Publication Details

Journal
World Journal of Diabetes
Published
2026-02-06
DOI
https://doi.org/10.4239/wjd.v17.i2.112867
Citations
1
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
30.73
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy

Huixia Cao, Pan He, Dan-Yu Wang, Feng-Min Shao et al.
1 citations
World Journal of Diabetes
Diabetes Treatment and Management
30.73
article

Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy

Huixia Cao, Pan He, Dan-Yu Wang, Feng-Min Shao, Lei Yan, Yan Miao
article en
1 citations

Abstract

CSCT provided significant improvements in multiple metabolic and renal parameters without increasing adverse events, thus highlighting its potential benefits for patients with DN.

World Journal of DiabetesVol. 17(2)
Henan Provincial People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 1%
Diabetes Treatment and Management
30.73
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Renal and metabolic effects of semaglutide plus canagliflozin <i>vs</i> canagliflozin alone in type 2 diabetic nephropathy — Huixia Cao, Pan He, et al. · World Journal of Diabetes (2026) | TGRS Research Map | TGRS